India's anti-obesity drug market is valued at Rs 3,000-3,500 crore and is projected to grow nearly eightfold to Rs 25,000 ...

More than 80 U.S. lawmakers asked the FDA to stop counterfeit GLP-1 drugs linked to Chinese suppliers from entering the ...

The global injectable drug delivery market is experiencing a significant transformation, poised to reach a staggering USD 113 ...

(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...

GLP-1 drugs have been compared to the discovery of penicillin, which changed the course of medicine by treating several ...

Pharma companies' earnings outlook is being obscured by concerns over revived "most-favored-nation" drug pricing rules in the ...

Initially, Dr Reddy's will focus on launching the generic semaglutide in Canada, India, Brazil, Turkey, and other emerging ...

During the pandemic, money flooded into drugmakers’ shares but recently more investors are shifting into Big Tech ...

Trump’s budget proposal, from May, seeks to slash the Department of Health and Human Services’ budget by $31.3 billion ...

Rhythm Pharmaceuticals' lone approved product currently generates minimal sales. If you're interested in capitalizing on the ...

Detailed price information for Compass Pathways Plc ADR (CMPS-Q) from The Globe and Mail including charting and trades.

Morgans healthcare and life sciences expert Iain Wilkie fills in for Scott Power this week, covering what the health movers ...